# Summary statistics - quantitative results

## EQA round: AKS2/24 - Basic Clinical Chemistry - Serum

Deadline: 5.4.2024

Setup: groups - M (measurement principle); minimal size of the groups n = 5

| | | |
|---|---|---|
| RoM = robust average | AV = assigned value | $D_{max}$ = acceptable difference |
| SD = standard deviation | CRV = certified reference value | LL = lower limit |
| CV = coefficient of variation | CVP = consensus of all participants | UL = upper limit |
| $N_{tot}$ = total number of the results | CVPG = consensus of the participants' groups | $N_{eva}$ = number of the results assessed |
| $N_{out}$ = number of the results removed before calculation | $U_{AV}$ = expanded uncertainty of the assigned value (k = 2) | $N_{suc}$ = number of successful results |
| | | $S_{rel}$ = relative success |

| Test / Sample / Group | [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Traceability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (22) **α-amylase** | [µkat/L] | | | | 362 | | | | | | | 0 | | | | | | | | 359 | 353 | 98 |
| **Sample A** | | 4,76 | 0,32 | 6,7 | 362 | | | | | | | 0 | | | | | | | | 359 | 354 | 99 |
| (0) Not specified | | 4,76 | 0,31 | 6,6 | 359 | 0 | | | | | | | | | CRV 4,79 | 0,13 | 15% | 4,07 | 5,51 | 359 | | |
| Other | | | | | 3 | 0 | | | | | | 0 | | | | | | | | 0 | | |
| | | | | | | | 3x 0/149 | | | | | | | | 3x 0/149 | | | | | | | |
| **Sample B** | | 3,35 | 0,15 | 4,6 | 362 | | | | | | | 0 | | | | | | | | 359 | 355 | 99 |
| (0) Not specified | | 3,35 | 0,15 | 4,5 | 359 | 0 | | | | | | | | | CRV 3,455 | 0,098 | 15% | 2,93 | 3,98 | 359 | | |
| Other | | | | | 3 | 0 | | | | | | 0 | | | | | | | | 0 | | |
| | | | | | | | 3x 0/149 | | | | | | | | 3x 0/149 | | | | | | | |
| (35) **α-amylase pancreatic** | [µkat/L] | | | | 127 | | | | | | | 127 | 127 | 100 | | | | | | 0 | | |
| **Sample A** | | | | | | | | | | | | 127 | 127 | 100 | | | | | | 0 | | |
| (0) Not specified | | 3,99 | 0,16 | 3,9 | 127 | 0 | CVP 3,99 | 0,034 | 18% | 3,27 | 4,71 | 127 | | | | | | | | | | |
| **Sample B** | | | | | | | | | | | | 127 | 127 | 100 | | | | | | 0 | | |
| (0) Not specified | | 2,48 | 0,1 | 4,1 | 127 | 0 | CVP 2,48 | 0,022 | 18% | 2,03 | 2,93 | 127 | | | | | | | | | | |
| (32) **γ-globulin (elfo)** | [-] | | | | 80 | | | | | | | 80 | 78 | 98 | | | | | | 0 | | |
| **Sample A** | | | | | | | | | | | | 80 | 79 | 99 | | | | | | 0 | | |
| (0) Not specified | | 0,125 | 0,013 | 11 | 80 | 0 | CVP 0,125 | 0,004 | 30% | 0,087 | 0,163 | 80 | | | | | | | | | | |
| **Sample B** | | | | | | | | | | | | 80 | 78 | 98 | | | | | | 0 | | |
| (0) Not specified | | 0,131 | 0,02 | 15 | 80 | 0 | CVP 0,131 | 0,005 | 30% | 0,091 | 0,171 | 80 | | | | | | | | | | |
| (10) **Albumin** | [g/L] | | | | 368 | | | | | | | 368 | 363 | 99 | | | | | | 0 | | |
| **Sample A** | | 39,4 | 1,3 | 3,3 | 368 | | CVP 39,4 | 0,16 | 10% | 35,4 | 43,4 | 368 | 367 | 100 | | | | | | 0 | | |
| (1) BCG | | 39,5 | 1,2 | 3 | 342 | 0 | | | | | | 342 | | | | | | | | | | |
| (2) BCP | | 37,1 | 1,5 | 4 | 26 | 0 | | | | | | 26 | | | | | | | | | | |
| **Sample B** | | 57,6 | 1,8 | 3,1 | 368 | | CVP 57,6 | 0,23 | 10% | 51,8 | 63,4 | 368 | 364 | 99 | | | | | | 0 | | |
| (1) BCG | | 57,7 | 1,7 | 3 | 342 | 0 | | | | | | 342 | | | | | | | | | | |
| (2) BCP | | 56,1 | 1,9 | 3,4 | 26 | 0 | | | | | | 26 | | | | | | | | | | |
| (31) **Albumin (elpho)** | [-] | | | | 80 | | | | | | | 80 | 78 | 98 | | | | | | 0 | | |
| **Sample A** | | | | | | | | | | | | 80 | 78 | 98 | | | | | | 0 | | |
| (0) Not specified | | 0,633 | 0,039 | 6,1 | 80 | 0 | CVP 0,633 | 0,011 | 15% | 0,538 | 0,728 | 80 | | | | | | | | | | |
| **Sample B** | | | | | | | | | | | | 80 | 79 | 99 | | | | | | 0 | | |
| (0) Not specified | | 0,614 | 0,062 | 10 | 80 | 0 | CVP 0,614 | 0,017 | 20% | 0,491 | 0,737 | 80 | | | | | | | | | | |
| (21) **ALP** | [µkat/L] | | | | 386 | | | | | | | 375 | 370 | 99 | | | | | | 386 | 354 | 92 |
| **Sample A** | | 1,85 | 0,13 | 7 | 386 | | | | | | | 375 | 372 | 99 | CRV 1,987 | 0,058 | 18% | 1,62 | 2,35 | 386 | 378 | 98 |
| (3) IFCC method | | 1,85 | 0,13 | 7 | 384 | 0 | | | | | | | | | | | | | | 384 | | |
| (3) IFCC method; (1) Abbott | | 1,93 | 0,073 | 3,8 | 101 | 0 | CVPG 1,93 | 0,018 | 14% | 1,65 | 2,21 | 101 | | | | | | | | | | |
| (3) IFCC method; (46) Erba Lachema | | 1,94 | 0,12 | 6,2 | 12 | 0 | CVPG 1,93 | 0,071 | 14% | 1,65 | 2,21 | 12 | | | | | | | | | | |
| (3) IFCC method; (58) Beckman Coulter (AU) | | 1,94 | 0,09 | 4,6 | 51 | 0 | CVPG 1,94 | 0,031 | 14% | 1,66 | 2,22 | 51 | | | | | | | | | | |
| (3) IFCC method; (60) Roche | | 1,78 | 0,082 | 4,6 | 146 | 0 | CVPG 1,78 | 0,017 | 14% | 1,53 | 2,03 | 146 | | | | | | | | | | |
| (3) IFCC method; (162) Siemens (Atellica) | | 1,71 | 0,083 | 4,8 | 32 | 0 | CVPG 1,71 | 0,036 | 14% | 1,47 | 1,95 | 32 | | | | | | | | | | |
| (3) IFCC method; (177) Mindray | | 1,86 | 0,079 | 4,2 | 12 | 0 | CVPG 1,86 | 0,056 | 14% | 1,59 | 2,13 | 12 | | | | | | | | | | |

# Summary statistics - quantitative results

## EQA round: AKS2/24 - Basic Clinical Chemistry - Serum

Deadline: 5.4.2024

Setup: groups - M (measurement principle); minimal size of the groups n = 5

| Test / Sample / Group | [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Traceability | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (3) IFCC method; (178) DiaSys | | 1,81 | 0,17 | 9,4 | 9 | 0 | CVPG | 1,81 | 0,21 | 14% | 1,55 | 2,07 | 9 | | | | | | | | | | | |
| (3) IFCC method; (179) Siemens | | 1,71 | 0,076 | 4,4 | 10 | 0 | CVPG | 1,71 | 0,059 | 14% | 1,47 | 1,95 | 10 | | | | | | | | | | | |
| Other | | | | | 2 | 0 | | | | | | | 2 | | | | | | | | | 2 | | |
| | | | | | | | 1x 1/1, 4x 3/12, 1x 3/73, 3x 3/149, 3x 3/158, 1x 99/46 | | | | | | | | | 1x 1, 1x 99 | | | | | | | | |
| **Sample B** | | 5,85 | 0,54 | 9,3 | 386 | | | | | | | | 375 | 371 | 99 | CRV | 6,28 | 0,18 | 18% | 5,14 | 7,42 | 386 | 356 | 92 |
| (3) IFCC method | | 5,84 | 0,54 | 9,3 | 384 | 0 | | | | | | | | | | | | | | | | 384 | | |
| (3) IFCC method; (1) Abbott | | 6,15 | 0,21 | 3,5 | 101 | 0 | CVPG | 6,15 | 0,052 | 14% | 5,28 | 7,02 | 101 | | | | | | | | | | | |
| (3) IFCC method; (46) Erba Lachema | | 6,24 | 0,28 | 4,6 | 12 | 0 | CVPG | 6,22 | 0,19 | 14% | 5,34 | 7,1 | 12 | | | | | | | | | | | |
| (3) IFCC method; (58) Beckman Coulter (AU) | | 6,52 | 0,32 | 4,9 | 51 | 0 | CVPG | 6,52 | 0,11 | 14% | 5,6 | 7,44 | 51 | | | | | | | | | | | |
| (3) IFCC method; (60) Roche | | 5,51 | 0,29 | 5,3 | 146 | 0 | CVPG | 5,51 | 0,059 | 14% | 4,73 | 6,29 | 146 | | | | | | | | | | | |
| (3) IFCC method; (162) Siemens (Atellica) | | 5,28 | 0,2 | 3,8 | 32 | 0 | CVPG | 5,28 | 0,087 | 14% | 4,54 | 6,02 | 32 | | | | | | | | | | | |
| (3) IFCC method; (177) Mindray | | 6,12 | 0,21 | 3,5 | 12 | 0 | CVPG | 6,12 | 0,15 | 14% | 5,26 | 6,98 | 12 | | | | | | | | | | | |
| (3) IFCC method; (178) DiaSys | | 5,73 | 0,38 | 6,6 | 9 | 0 | CVPG | 5,73 | 0,47 | 14% | 4,92 | 6,54 | 9 | | | | | | | | | | | |
| (3) IFCC method; (179) Siemens | | 5,26 | 0,24 | 4,7 | 10 | 0 | CVPG | 5,26 | 0,19 | 14% | 4,52 | 6 | 10 | | | | | | | | | | | |
| Other | | | | | 2 | 0 | | | | | | | 2 | | | | | | | | | 2 | | |
| | | | | | | | 1x 1/1, 4x 3/12, 1x 3/73, 3x 3/149, 3x 3/158, 1x 99/46 | | | | | | | | | 1x 1, 1x 99 | | | | | | | | |
| (24) **ALT** | [µkat/L] | | | | 390 | | | | | | | | 0 | | | | | | | | | 390 | 379 | 97 |
| **Sample A** | | | | | | | | | | | | | 0 | | | | | | | | | 390 | 380 | 97 |
| (0) Not specified | | 0,878 | 0,057 | 6,5 | 390 | 0 | | | | | | | | | | CRV | 0,827 | 0,022 | asym. | 0,702 | 1,01 | 390 | | |
| **Sample B** | | | | | | | | | | | | | 0 | | | | | | | | | 390 | 389 | 100 |
| (0) Not specified | | 3,57 | 0,18 | 5,1 | 390 | 0 | | | | | | | | | | CRV | 3,649 | 0,081 | 15% | 3,1 | 4,2 | 390 | | |
| (23) **AST** | [µkat/L] | | | | 391 | | | | | | | | 0 | | | | | | | | | 391 | 388 | 99 |
| **Sample A** | | | | | | | | | | | | | 0 | | | | | | | | | 391 | 390 | 100 |
| (0) Not specified | | 2,02 | 0,081 | 4 | 391 | 0 | | | | | | | | | | CRV | 1,983 | 0,048 | 15% | 1,68 | 2,29 | 391 | | |
| **Sample B** | | | | | | | | | | | | | 0 | | | | | | | | | 391 | 389 | 99 |
| (0) Not specified | | 4,75 | 0,21 | 4,5 | 391 | 0 | | | | | | | | | | CRV | 4,66 | 0,1 | 15% | 3,96 | 5,36 | 391 | | |
| (13) **Bilirubin total** | [µmol/L] | | | | 390 | | | | | | | | 0 | | | | | | | | | 390 | 389 | 100 |
| **Sample A** | | 32,6 | 3,3 | 10 | 390 | | | | | | | | 0 | | | CRV | 31,69 | 0,76 | 26% | 23,4 | 40 | 390 | 389 | 100 |
| (1) Jendrassik-Gróf | | 33,3 | 3,1 | 9,2 | 44 | 0 | | | | | | | | | | | | | | | | 44 | | |
| (2) DCA, DPD | | 32,1 | 3,2 | 10 | 301 | 0 | | | | | | | | | | | | | | | | 301 | | |
| (4) Oxidation-reduction methods | | 34,8 | 2,1 | 6 | 45 | 0 | | | | | | | | | | | | | | | | 45 | | |
| **Sample B** | | 65,7 | 5,4 | 8,2 | 390 | | | | | | | | 0 | | | CRV | 65 | 1,5 | 26% | 48,1 | 81,9 | 390 | 389 | 100 |
| (1) Jendrassik-Gróf | | 67,3 | 5,5 | 8,1 | 44 | 0 | | | | | | | | | | | | | | | | 44 | | |
| (2) DCA, DPD | | 64,7 | 4,8 | 7,5 | 301 | 0 | | | | | | | | | | | | | | | | 301 | | |
| (4) Oxidation-reduction methods | | 70,5 | 4,2 | 6 | 45 | 0 | | | | | | | | | | | | | | | | 45 | | |
| (14) **Bilirubin direct** | [µmol/L] | | | | 273 | | | | | | | | 240 | 220 | 92 | | | | | | | 0 | | |
| **Sample A** | | 8,83 | 2 | 23 | 273 | | | | | | | | 240 | 222 | 93 | | | | | | | 0 | | |
| (0) Not specified; (0) not specified | | 7,94 | 2 | 25 | 20 | 0 | CVPG | 7,94 | 1,1 | 20% | 6,35 | 9,53 | 0 | | | | | | | | | | | |
| (1) Jendrassik-Gróf; (1) Abbott | | 8,9 | 0 | 0 | 5 | 0 | CVPG | 8,93 | 0,12 | 20% | 7,14 | 10,8 | 5 | | | | | | | | | | | |
| (1) Jendrassik-Gróf; (60) Roche | | 9,33 | 1,1 | 12 | 14 | 0 | CVPG | 9,36 | 0,24 | 20% | 7,48 | 11,3 | 14 | | | | | | | | | | | |
| (2) DCA, DPD; (1) Abbott | | 8,93 | 0,41 | 4,6 | 61 | 0 | CVPG | 8,93 | 0,12 | 20% | 7,14 | 10,8 | 61 | | | | | | | | | | | |
| (2) DCA, DPD; (58) Beckman Coulter (AU) | | 5,32 | 0,62 | 12 | 32 | 0 | CVPG | 5,35 | 0,25 | 20% | 4,28 | 6,42 | 32 | | | | | | | | | | | |
| (2) DCA, DPD; (60) Roche | | 9,35 | 0,92 | 9,9 | 80 | 0 | CVPG | 9,36 | 0,24 | 20% | 7,48 | 11,3 | 80 | | | | | | | | | | | |
| (4) Oxidation-reduction methods; (162) Siemens (Atellica) | | 11,6 | 0,62 | 5,4 | 25 | 0 | CVPG | 11,5 | 0,35 | 20% | 9,2 | 13,8 | 25 | | | | | | | | | | | |
| (4) Oxidation-reduction methods; (179) Siemens | | 10,4 | 0,89 | 8,6 | 8 | 0 | CVPG | 10,3 | 0,82 | 20% | 8,24 | 12,4 | 8 | | | | | | | | | | | |

# Summary statistics - quantitative results

## EQA round: AKS2/24 - Basic Clinical Chemistry - Serum

Deadline: 5.4.2024

Setup: groups - M (measurement principle); minimal size of the groups n = 5

| Test / Sample / Group | [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Traceability | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other | | | | | 28 | 0 | | | | | | | 15 | | | | | | | | | | | |
| | | | | | | | 1x 1/46, 3x 1/58, 1x 1/149, 1x 1/158, 3x 1/177, 1x 1/179, 2x 2/12, 1x 2/18, 2x 2/46, 3x 2/162, 3x 2/177, 3x 2/178, 1x 4/1, 2x 4/70, 1x 99/60 | | | | | | | | | | | | | | | | |
| **Sample B** | | 14,3 | 3,5 | 24 | 273 | | | | | | | | 240 | 222 | 93 | | | | | | | 0 | | |
| (0) Not specified; (0) not specified | | 12,6 | 3,1 | 25 | 20 | 0 | CVPG | 12,6 | 1,7 | 20% | 10 | 15,2 | 0 | | | | | | | | | | | |
| (1) Jendrassik-Gróf; (1) Abbott | | 14 | 0,22 | 1,6 | 5 | 0 | CVPG | 13,9 | 0,18 | 20% | 11,1 | 16,7 | 5 | | | | | | | | | | | |
| (1) Jendrassik-Gróf; (60) Roche | | 15,5 | 1,6 | 11 | 14 | 0 | CVPG | 15,7 | 0,44 | 20% | 12,5 | 18,9 | 14 | | | | | | | | | | | |
| (2) DCA, DPD; (1) Abbott | | 13,9 | 0,62 | 4,4 | 61 | 0 | CVPG | 13,9 | 0,18 | 20% | 11,1 | 16,7 | 61 | | | | | | | | | | | |
| (2) DCA, DPD; (58) Beckman Coulter (AU) | | 8,45 | 1,1 | 13 | 32 | 0 | CVPG | 8,49 | 0,42 | 20% | 6,79 | 10,2 | 32 | | | | | | | | | | | |
| (2) DCA, DPD; (60) Roche | | 15,6 | 1,8 | 11 | 80 | 0 | CVPG | 15,7 | 0,44 | 20% | 12,5 | 18,9 | 80 | | | | | | | | | | | |
| (4) Oxidation-reduction methods; (162) Siemens (Atellica) | | 19,1 | 0,95 | 5 | 25 | 0 | CVPG | 18,9 | 0,53 | 20% | 15,1 | 22,7 | 25 | | | | | | | | | | | |
| (4) Oxidation-reduction methods; (179) Siemens | | 16,5 | 0,82 | 5 | 8 | 0 | CVPG | 16,5 | 1 | 20% | 13,2 | 19,8 | 8 | | | | | | | | | | | |
| Other | | | | | 28 | 0 | | | | | | | 15 | | | | | | | | | | | |
| | | | | | | | 1x 1/46, 3x 1/58, 1x 1/149, 1x 1/158, 3x 1/177, 1x 1/179, 2x 2/12, 1x 2/18, 2x 2/46, 3x 2/162, 3x 2/177, 3x 2/178, 1x 4/1, 2x 4/70, 1x 99/60 | | | | | | | | | | | | | | | | |
| (9) **Total protein** | [g/L] | | | | 373 | | | | | | | | 0 | | | | | | | | | 373 | 366 | 98 |
| **Sample A** | | | | | | | | | | | | | 0 | | | | | | | | | 373 | 370 | 99 |
| (0) Not specified | | 61,2 | 1,4 | 2,3 | 373 | 0 | | | | | | | | | | CRV | 61,1 | 1,4 | 9% | 55,6 | 66,6 | 373 | | |
| **Sample B** | | | | | | | | | | | | | 0 | | | | | | | | | 373 | 368 | 99 |
| (0) Not specified | | 93,1 | 2,5 | 2,7 | 373 | 0 | | | | | | | | | | CRV | 95,4 | 2,8 | 9% | 86,8 | 104 | 373 | | |
| (26) **CK** | [µkat/L] | | | | 351 | | | | | | | | 0 | | | | | | | | | 351 | 332 | 95 |
| **Sample A** | | | | | | | | | | | | | 0 | | | | | | | | | 351 | 350 | 100 |
| (0) Not specified | | 3,2 | 0,18 | 5,5 | 351 | 0 | | | | | | | | | | CRV | 3,417 | 0,083 | 20% | 2,73 | 4,11 | 351 | | |
| **Sample B** | | | | | | | | | | | | | 0 | | | | | | | | | 351 | 333 | 95 |
| (0) Not specified | | 3,66 | 0,27 | 7,4 | 351 | 0 | | | | | | | | | | CRV | 4,007 | 0,096 | 20% | 3,2 | 4,81 | 351 | | |
| (2) **Potassium** | [mmol/L] | | | | 387 | | | | | | | | 0 | | | | | | | | | 387 | 382 | 99 |
| **Sample A** | | 3,66 | 0,07 | 1,9 | 387 | | | | | | | | 0 | | | CRV | 3,619 | 0,064 | 7% | 3,36 | 3,88 | 387 | 385 | 99 |
| (2) Indirect ISE | | 3,66 | 0,066 | 1,8 | 349 | 0 | | | | | | | | | | | | | | | | 349 | | |
| (3) Direct ISE | | 3,66 | 0,1 | 2,8 | 37 | 0 | | | | | | | | | | | | | | | | 37 | | |
| Other | | | | | 1 | 0 | | | | | | | | | | | | | | | | 1 | | |
| | | | | | | | | | | | | | | | | 1x 99 | | | | | | | | |
| **Sample B** | | 7 | 0,12 | 1,7 | 387 | | | | | | | | 0 | | | CRV | 6,94 | 0,11 | 7% | 6,45 | 7,43 | 387 | 383 | 99 |
| (2) Indirect ISE | | 7,01 | 0,11 | 1,6 | 349 | 0 | | | | | | | | | | | | | | | | 349 | | |
| (3) Direct ISE | | 6,98 | 0,17 | 2,4 | 37 | 0 | | | | | | | | | | | | | | | | 37 | | |
| Other | | | | | 1 | 0 | | | | | | | | | | | | | | | | 1 | | |
| | | | | | | | | | | | | | | | | 1x 99 | | | | | | | | |
| (5) **Inorganic phosphate** | [mmol/L] | | | | 351 | | | | | | | | 351 | 343 | 98 | | | | | | | 0 | | |
| **Sample A** | | 1,03 | 0,032 | 3,1 | 351 | | CVP | 1,03 | 0,004 | 10% | 0,927 | 1,14 | 351 | 346 | 99 | | | | | | | 0 | | |
| (1) UV-molybdate method | | 1,03 | 0,032 | 3,1 | 344 | 0 | | | | | | | 344 | | | | | | | | | | | |
| Other | | | | | 7 | 0 | | | | | | | 7 | | | | | | | | | | | |
| | | | | | | | 4x 2, 3x 3 | | | | | | | | | | | | | | | | | |
| **Sample B** | | 2,03 | 0,055 | 2,7 | 351 | | CVP | 2,03 | 0,007 | 10% | 1,82 | 2,24 | 351 | 347 | 99 | | | | | | | 0 | | |
| (1) UV-molybdate method | | 2,03 | 0,055 | 2,7 | 344 | 0 | | | | | | | 344 | | | | | | | | | | | |
| Other | | | | | 7 | 0 | | | | | | | 7 | | | | | | | | | | | |
| | | | | | | | 4x 2, 3x 3 | | | | | | | | | | | | | | | | | |

# Summary statistics - quantitative results

## EQA round: AKS2/24 - Basic Clinical Chemistry - Serum

Deadline: 5.4.2024

Setup: groups - M (measurement principle); minimal size of the groups n = 5

| Test / Sample / Group | [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Traceability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (27) **gamma-GT** | [µkat/L] | | | | 387 | | | | | | | 0 | | | | | | | | 387 | 387 | 100 |
| **Sample A** | | | | | | | | | | | | 0 | | | | | | | | 387 | 387 | 100 |
| (0) Not specified | | 1,98 | 0,061 | 3,1 | 387 | 0 | | | | | | | | | CRV | 2,052 | 0,053 | 21% | 1,62 | 2,49 | 387 | |
| **Sample B** | | | | | | | | | | | | 0 | | | | | | | | 387 | 387 | 100 |
| (0) Not specified | | 3,28 | 0,1 | 3,1 | 387 | 0 | | | | | | | | | CRV | 3,352 | 0,082 | 21% | 2,64 | 4,06 | 387 | |
| (16) **Glucose** | [mmol/L] | | | | 392 | | | | | | | 0 | | | | | | | | 392 | 386 | 98 |
| **Sample A** | | 5,38 | 0,15 | 2,7 | 392 | | | | | | | 0 | | | CRV | 5,542 | 0,055 | asym. | 4,87 | 5,99 | 392 | 390 | 99 |
| (1) GOD photometry | | 5,46 | 0,17 | 3,1 | 58 | 0 | | | | | | | | | | | | | | | 58 | | |
| (3) Method with hexokinase | | 5,37 | 0,14 | 2,6 | 333 | 0 | | | | | | | | | | | | | | | 333 | | |
| Other | | | | | 1 | 0 | | | | | | | | | | | | | | | 1 | | |
| | | | | | | | | | | | | | | | 1x 2 | | | | | | | | |
| **Sample B** | | 6,52 | 0,18 | 2,7 | 392 | | | | | | | 0 | | | CRV | 6,818 | 0,068 | asym. | 5,99 | 7,37 | 392 | 387 | 99 |
| (1) GOD photometry | | 6,61 | 0,2 | 3 | 58 | 0 | | | | | | | | | | | | | | | 58 | | |
| (3) Method with hexokinase | | 6,51 | 0,17 | 2,6 | 333 | 0 | | | | | | | | | | | | | | | 333 | | |
| Other | | | | | 1 | 0 | | | | | | | | | | | | | | | 1 | | |
| | | | | | | | | | | | | | | | 1x 2 | | | | | | | | |
| (7) **Magnesium** | [mmol/L] | | | | 345 | | | | | | | 0 | | | | | | | | 345 | 343 | 99 |
| **Sample A** | | 1,2 | 0,032 | 2,7 | 345 | | | | | | | 0 | | | CRV | 1,191 | 0,023 | 15% | 1,01 | 1,37 | 345 | 344 | 100 |
| (2) Photometry | | 1,2 | 0,031 | 2,6 | 256 | 0 | | | | | | | | | | | | | | | 256 | | |
| (4) UV enzyme method | | 1,2 | 0,036 | 3 | 88 | 0 | | | | | | | | | | | | | | | 88 | | |
| Other | | | | | 1 | 0 | | | | | | | | | | | | | | | 1 | | |
| | | | | | | | | | | | | | | | 1x 99 | | | | | | | | |
| **Sample B** | | 1,02 | 0,029 | 2,8 | 345 | | | | | | | 0 | | | CRV | 1,008 | 0,02 | 15% | 0,856 | 1,16 | 345 | 344 | 100 |
| (2) Photometry | | 1,03 | 0,027 | 2,6 | 256 | 0 | | | | | | | | | | | | | | | 256 | | |
| (4) UV enzyme method | | 1,02 | 0,032 | 3,2 | 88 | 0 | | | | | | | | | | | | | | | 88 | | |
| Other | | | | | 1 | 0 | | | | | | | | | | | | | | | 1 | | |
| | | | | | | | | | | | | | | | 1x 99 | | | | | | | | |
| (3) **Chloride** | [mmol/L] | | | | 387 | | | | | | | 387 | 384 | 99 | | | | | | 0 | | |
| **Sample A** | | 102 | 3,3 | 3,3 | 387 | | CVP | 102 | 0,42 | 7% | 94,8 | 110 | 387 | 386 | 100 | | | | | | 0 | | |
| (3) Indirect ISE | | 103 | 3,4 | 3,3 | 349 | 0 | | | | | | | 349 | | | | | | | | | | |
| (4) Direct ISE | | 102 | 3,2 | 3,2 | 37 | 0 | | | | | | | 37 | | | | | | | | | | |
| Other | | | | | 1 | 0 | | | | | | | 1 | | | | | | | | | | |
| | | | | | | | 1x 99 | | | | | | | | | | | | | | | | |
| **Sample B** | | 133 | 3,4 | 2,5 | 387 | | CVP | 133 | 0,42 | 7% | 123 | 143 | 387 | 385 | 99 | | | | | | 0 | | |
| (3) Indirect ISE | | 133 | 3,3 | 2,5 | 349 | 0 | | | | | | | 349 | | | | | | | | | | |
| (4) Direct ISE | | 133 | 3,5 | 2,7 | 37 | 0 | | | | | | | 37 | | | | | | | | | | |
| Other | | | | | 1 | 0 | | | | | | | 1 | | | | | | | | | | |
| | | | | | | | 1x 99 | | | | | | | | | | | | | | | | |
| (15) **Cholesterol** | [mmol/L] | | | | 377 | | | | | | | 0 | | | | | | | | 374 | 371 | 99 |
| **Sample A** | | 4,13 | 0,11 | 2,6 | 377 | | | | | | | 0 | | | | | | | | 374 | 372 | 99 |
| (0) Not specified | | 4,13 | 0,11 | 2,6 | 374 | 0 | | | | | | | | | CRV | 4,145 | 0,041 | 9% | 3,77 | 4,52 | 374 | |
| Other | | | | | 3 | 0 | | | | | | 0 | | | | | | | | 0 | | |
| | | | | | | | 3x 0/149 | | | | | | | | 3x 0/149 | | | | | | | | |
| **Sample B** | | 5,82 | 0,16 | 2,7 | 377 | | | | | | | 0 | | | | | | | | 374 | 372 | 99 |
| (0) Not specified | | 5,82 | 0,16 | 2,7 | 374 | 0 | | | | | | | | | CRV | 5,933 | 0,066 | 9% | 5,39 | 6,47 | 374 | |

# Summary statistics - quantitative results

## EQA round: AKS2/24 - Basic Clinical Chemistry - Serum

Deadline: 5.4.2024

Setup: groups - M (measurement principle); minimal size of the groups n = 5

| Test / Sample / Group | [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Traceability | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other | | | | | 3 | 0 | 3x 0/149 | | | | | | 0 | | | 3x 0/149 | | | | | | 0 | | |
| (30) **Cholinesterase** | [µkat/L] | | | | 112 | | | | | | | | 112 | 105 | 94 | | | | | | | 0 | | |
| **Sample A** | | 118 | 5,4 | 4,6 | 112 | | | | | | | | 112 | 105 | 94 | | | | | | | 0 | | |
| (0) Not specified | | 117 | 4,6 | 3,9 | 106 | 0 | CVP | 117 | 1,1 | 12% | 102 | 132 | 106 | | | | | | | | | | | |
| (0) Not specified; (162) Siemens (Atellica) | | 181 | 2,8 | 1,6 | 6 | 0 | CVPG | 181 | 3,9 | 10% | 162 | 200 | 6 | | | | | | | | | | | |
| **Sample B** | | 168 | 8,1 | 4,9 | 112 | | | | | | | | 112 | 106 | 95 | | | | | | | 0 | | |
| (0) Not specified | | 167 | 6,9 | 4,1 | 106 | 0 | CVP | 167 | 1,6 | 12% | 146 | 188 | 106 | | | | | | | | | | | |
| (0) Not specified; (162) Siemens (Atellica) | | 259 | 2,7 | 1 | 6 | 0 | CVPG | 259 | 3,7 | 10% | 233 | 285 | 6 | | | | | | | | | | | |
| (19) **Creatinine** | [µmol/L] | | | | 390 | | | | | | | | 0 | | | | | | | | | 390 | 369 | 95 |
| **Sample A** | | 87,6 | 3,7 | 4,2 | 390 | | | | | | | | 0 | | | CRV | 88,27 | 0,88 | 13% | 76,7 | 99,8 | 390 | 384 | 98 |
| (1) Jaffe | | 88,6 | 4,5 | 5,1 | 156 | 0 | | | | | | | | | | | | | | | | 156 | | |
| (3) Enzyme | | 87 | 3,1 | 3,5 | 234 | 0 | | | | | | | | | | | | | | | | 234 | | |
| **Sample B** | | 151 | 7,9 | 5,3 | 390 | | | | | | | | 0 | | | CRV | 146,7 | 1,5 | 13% | 127 | 166 | 390 | 372 | 95 |
| (1) Jaffe | | 157 | 8,9 | 5,7 | 156 | 0 | | | | | | | | | | | | | | | | 156 | | |
| (3) Enzyme | | 147 | 4,6 | 3,1 | 234 | 0 | | | | | | | | | | | | | | | | 234 | | |
| (17) **Uric acid** | [µmol/L] | | | | 386 | | | | | | | | 0 | | | | | | | | | 386 | 384 | 99 |
| **Sample A** | | | | | | | | | | | | | 0 | | | | | | | | | 386 | 386 | 100 |
| (0) Not specified | | 537 | 14 | 2,6 | 386 | 0 | | | | | | | | | | CRV | 532,6 | 5,3 | 12% | 468 | 597 | 386 | | |
| **Sample B** | | | | | | | | | | | | | 0 | | | | | | | | | 386 | 384 | 99 |
| (0) Not specified | | 200 | 5,7 | 2,9 | 386 | 0 | | | | | | | | | | CRV | 203,1 | 2 | 12% | 178 | 228 | 386 | | |
| (12) **Lactate** | [mmol/L] | | | | 160 | | | | | | | | 160 | 158 | 99 | | | | | | | 0 | | |
| **Sample A** | | 2,97 | 0,087 | 2,9 | 160 | | CVP | 2,97 | 0,017 | 15% | 2,52 | 3,42 | 160 | 159 | 99 | | | | | | | 0 | | |
| (1) UV enzyme method | | 2,95 | 0,079 | 2,7 | 55 | 0 | | | | | | | 55 | | | | | | | | | | | |
| (2) Enzyme electrodes | | 3,01 | 0,16 | 5,4 | 9 | 0 | | | | | | | 9 | | | | | | | | | | | |
| (3) Photometric enzyme method | | 2,97 | 0,087 | 2,9 | 96 | 0 | | | | | | | 96 | | | | | | | | | | | |
| **Sample B** | | 4,68 | 0,14 | 2,9 | 160 | | CVP | 4,68 | 0,026 | 15% | 3,97 | 5,39 | 160 | 158 | 99 | | | | | | | 0 | | |
| (1) UV enzyme method | | 4,66 | 0,12 | 2,6 | 55 | 0 | | | | | | | 55 | | | | | | | | | | | |
| (2) Enzyme electrodes | | 4,72 | 0,47 | 10 | 9 | 0 | | | | | | | 9 | | | | | | | | | | | |
| (3) Photometric enzyme method | | 4,68 | 0,13 | 2,8 | 96 | 0 | | | | | | | 96 | | | | | | | | | | | |
| (28) **LD** | [µkat/L] | | | | 285 | | | | | | | | 0 | | | | | | | | | 285 | 285 | 100 |
| **Sample A** | | | | | | | | | | | | | 0 | | | | | | | | | 285 | 285 | 100 |
| (0) Not specified | | 4,93 | 0,18 | 3,7 | 285 | 0 | | | | | | | | | | CRV | 4,87 | 0,11 | 18% | 3,99 | 5,75 | 285 | | |
| **Sample B** | | | | | | | | | | | | | 0 | | | | | | | | | 285 | 285 | 100 |
| (0) Not specified | | 4,59 | 0,16 | 3,5 | 285 | 0 | | | | | | | | | | CRV | 4,6 | 0,12 | 18% | 3,77 | 5,43 | 285 | | |
| (29) **Lipase** | [µkat/L] | | | | 199 | | | | | | | | 185 | 185 | 100 | | | | | | | 0 | | |
| **Sample A** | | 2 | 0,16 | 7,9 | 199 | | | | | | | | 185 | 185 | 100 | | | | | | | 0 | | |
| (0) Not specified; (1) Abbott | | 1,94 | 0,09 | 4,6 | 38 | 0 | CVPG | 1,94 | 0,036 | 24% | 1,47 | 2,41 | 38 | | | | | | | | | | | |
| (0) Not specified; (58) Beckman Coulter (AU) | | 1,92 | 0,072 | 3,7 | 30 | 0 | CVPG | 1,92 | 0,032 | 24% | 1,45 | 2,39 | 30 | | | | | | | | | | | |
| (0) Not specified; (60) Roche | | 2,02 | 0,094 | 4,7 | 79 | 0 | CVPG | 2,02 | 0,026 | 24% | 1,53 | 2,51 | 79 | | | | | | | | | | | |
| (0) Not specified; (116) Sentinel Diagnostics | | 1,85 | 0,14 | 7,6 | 9 | 0 | CVPG | 1,85 | 0,17 | 24% | 1,4 | 2,3 | 9 | | | | | | | | | | | |
| (0) Not specified; (162) Siemens (Atellica) | | 2,28 | 0,048 | 2,1 | 24 | 0 | CVPG | 2,28 | 0,024 | 24% | 1,73 | 2,83 | 24 | | | | | | | | | | | |
| (0) Not specified; (179) Siemens | | 2,19 | 0,35 | 16 | 5 | 0 | CVPG | 2,19 | 0,98 | 24% | 1,66 | 2,72 | 5 | | | | | | | | | | | |
| Other | | | | | 14 | 0 | 2x 0/12, 2x 0/46, 2x 0/49, 1x 0/149, 1x 0/166, 2x 0/177, 4x 0/178 | | | | | | 0 | | | | | | | | | | | |

# Summary statistics - quantitative results

## EQA round: AKS2/24 - Basic Clinical Chemistry - Serum

Deadline: 5.4.2024

Setup: groups - M (measurement principle); minimal size of the groups n = 5

| Test / Sample / Group | [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Traceability | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Sample B** | | 2,9 | 0,26 | 9 | 199 | | | | | | | | 185 | 185 | 100 | | | | | | | 0 | | |
| (0) Not specified; (1) Abbott | | 2,71 | 0,13 | 4,7 | 38 | 0 | CVPG | 2,71 | 0,051 | 24% | 2,05 | 3,37 | 38 | | | | | | | | | | | |
| (0) Not specified; (58) Beckman Coulter (AU) | | 2,77 | 0,11 | 3,8 | 30 | 0 | CVPG | 2,77 | 0,047 | 24% | 2,1 | 3,44 | 30 | | | | | | | | | | | |
| (0) Not specified; (60) Roche | | 2,97 | 0,14 | 4,7 | 79 | 0 | CVPG | 2,97 | 0,039 | 24% | 2,25 | 3,69 | 79 | | | | | | | | | | | |
| (0) Not specified; (116) Sentinel Diagnostics | | 2,7 | 0,082 | 3 | 9 | 0 | CVPG | 2,7 | 0,1 | 24% | 2,05 | 3,35 | 9 | | | | | | | | | | | |
| (0) Not specified; (162) Siemens (Atellica) | | 3,37 | 0,11 | 3,1 | 24 | 0 | CVPG | 3,37 | 0,053 | 24% | 2,56 | 4,18 | 24 | | | | | | | | | | | |
| (0) Not specified; (179) Siemens | | 3,21 | 0,53 | 17 | 5 | 0 | CVPG | 3,21 | 1,5 | 24% | 2,43 | 3,99 | 5 | | | | | | | | | | | |
| Other | | | | | 14 | 0 | | | | | | | 0 | | | | | | | | | | | |
| | | | | | | | 2x 0/12, 2x 0/46, 2x 0/49, 1x 0/149, 1x 0/166, 2x 0/177, 4x 0/178 | | | | | | | | | | | | | | | | | |
| (8) **Lithium** | [mmol/L] | | | | 47 | | | | | | | | 0 | | | | | | | | | 47 | 43 | 91 |
| **Sample A** | | 1,55 | 0,058 | 3,7 | 47 | | | | | | | | 0 | | | CRV | 1,612 | 0,024 | 12% | 1,41 | 1,81 | 47 | 45 | 96 |
| (3) ISE | | 1,53 | 0,045 | 2,9 | 8 | 0 | | | | | | | | | | | | | | | | 8 | | |
| (4) Photometry | | 1,55 | 0,047 | 3 | 31 | 0 | | | | | | | | | | | | | | | | 31 | | |
| Other | | | | | 8 | 0 | | | | | | | | | | | | | | | | 8 | | |
| | | | | | | | | | | | | | | | | 4x 1, 4x 2 | | | | | | | | |
| **Sample B** | | 0,917 | 0,038 | 4,1 | 47 | | | | | | | | 0 | | | CRV | 0,947 | 0,014 | 12% | 0,833 | 1,07 | 47 | 44 | 94 |
| (3) ISE | | 0,93 | 0,059 | 6,4 | 8 | 0 | | | | | | | | | | | | | | | | 8 | | |
| (4) Photometry | | 0,913 | 0,026 | 2,8 | 31 | 0 | | | | | | | | | | | | | | | | 31 | | |
| Other | | | | | 8 | 0 | | | | | | | | | | | | | | | | 8 | | |
| | | | | | | | | | | | | | | | | 4x 1, 4x 2 | | | | | | | | |
| (18) **Urea** | [mmol/L] | | | | 389 | | | | | | | | 0 | | | | | | | | | 389 | 384 | 99 |
| **Sample A** | | 9,54 | 0,39 | 4,1 | 389 | | | | | | | | 0 | | | CRV | 9,7 | 0,1 | 15% | 8,24 | 11,2 | 389 | 384 | 99 |
| (1) UV enzymatic m.(GMD) | | 9,54 | 0,39 | 4,1 | 387 | 0 | | | | | | | | | | | | | | | | 387 | | |
| Other | | | | | 2 | 0 | | | | | | | | | | | | | | | | 2 | | |
| | | | | | | | | | | | | | | | | 2x 2 | | | | | | | | |
| **Sample B** | | 19,9 | 0,61 | 3,1 | 389 | | | | | | | | 0 | | | CRV | 20,01 | 0,2 | 15% | 17 | 23,1 | 389 | 387 | 99 |
| (1) UV enzymatic m.(GMD) | | 19,9 | 0,61 | 3,1 | 387 | 0 | | | | | | | | | | | | | | | | 387 | | |
| Other | | | | | 2 | 0 | | | | | | | | | | | | | | | | 2 | | |
| | | | | | | | | | | | | | | | | 2x 2 | | | | | | | | |
| (11) **Osmolality** | [mmol/kg] | | | | 132 | | | | | | | | 132 | 130 | 98 | | | | | | | 0 | | |
| **Sample A** | | | | | | | | | | | | | 132 | 130 | 98 | | | | | | | 0 | | |
| (0) Not specified | | 267 | 4,9 | 1,8 | 132 | 0 | CVP | 267 | 1 | 5% | 253 | 281 | 132 | | | | | | | | | | | |
| **Sample B** | | | | | | | | | | | | | 132 | 132 | 100 | | | | | | | 0 | | |
| (0) Not specified | | 343 | 7,1 | 2,1 | 132 | 0 | CVP | 343 | 1,5 | 5% | 325 | 361 | 132 | | | | | | | | | | | |
| (1) **Sodium** | [mmol/L] | | | | 387 | | | | | | | | 0 | | | | | | | | | 387 | 384 | 99 |
| **Sample A** | | 123 | 1,9 | 1,6 | 387 | | | | | | | | 0 | | | CRV | 123,3 | 1,8 | 5% | 117 | 130 | 387 | 385 | 99 |
| (2) Indirect ISE | | 123 | 1,9 | 1,6 | 349 | 0 | | | | | | | | | | | | | | | | 349 | | |
| (3) Direct ISE | | 123 | 2,1 | 1,7 | 37 | 0 | | | | | | | | | | | | | | | | 37 | | |
| Other | | | | | 1 | 0 | | | | | | | | | | | | | | | | 1 | | |
| | | | | | | | | | | | | | | | | 1x 99 | | | | | | | | |
| **Sample B** | | 151 | 2,1 | 1,4 | 387 | | | | | | | | 0 | | | CRV | 152,8 | 2,3 | 5% | 145 | 161 | 387 | 385 | 99 |
| (2) Indirect ISE | | 151 | 2 | 1,3 | 349 | 0 | | | | | | | | | | | | | | | | 349 | | |
| (3) Direct ISE | | 153 | 3,9 | 2,5 | 37 | 0 | | | | | | | | | | | | | | | | 37 | | |
| Other | | | | | 1 | 0 | | | | | | | | | | | | | | | | 1 | | |
| | | | | | | | | | | | | | | | | 1x 99 | | | | | | | | |

# Summary statistics - quantitative results

## EQA round: AKS2/24 - Basic Clinical Chemistry - Serum

Deadline: 5.4.2024

Setup: groups - M (measurement principle); minimal size of the groups n = 5

| Test / Sample / Group | [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability | | | | | | | | | Traceability | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
| (20) **Triacylglycerols** | [mmol/L] | | | | 377 | | | | | | | | 0 | | | | | | | | | 377 | 372 | 99 |
| **Sample A** | | 1,38 | 0,06 | 4,4 | 377 | | | | | | | | 0 | | | CRV | 1,386 | 0,014 | 18% | 1,13 | 1,64 | 377 | 372 | 99 |
| (1) Photometric enzyme (GPO-PAP) | | 1,38 | 0,06 | 4,4 | 364 | 0 | | | | | | | | | | | | | | | | 364 | | |
| (2) Enzymatic UV method | | 1,41 | 0,073 | 5,2 | 13 | 0 | | | | | | | | | | | | | | | | 13 | | |
| **Sample B** | | 1,52 | 0,076 | 5 | 377 | | | | | | | | 0 | | | CRV | 1,546 | 0,015 | 18% | 1,26 | 1,83 | 377 | 375 | 99 |
| (1) Photometric enzyme (GPO-PAP) | | 1,52 | 0,075 | 4,9 | 364 | 0 | | | | | | | | | | | | | | | | 364 | | |
| (2) Enzymatic UV method | | 1,56 | 0,11 | 7,1 | 13 | 0 | | | | | | | | | | | | | | | | 13 | | |
| (4) **Calcium** | [mmol/L] | | | | 371 | | | | | | | | 0 | | | | | | | | | 371 | 366 | 99 |
| **Sample A** | | 2,46 | 0,054 | 2,2 | 371 | | | | | | | | 0 | | | CRV | 2,441 | 0,037 | 8% | 2,24 | 2,64 | 371 | 368 | 99 |
| (2) Phot. with o-cresolftalexon | | 2,46 | 0,066 | 2,7 | 25 | 0 | | | | | | | | | | | | | | | | 25 | | |
| (3) Photom. with arsenazo III | | 2,45 | 0,059 | 2,4 | 216 | 0 | | | | | | | | | | | | | | | | 216 | | |
| (4) Photomet. with NM-BAPTA | | 2,47 | 0,043 | 1,7 | 128 | 0 | | | | | | | | | | | | | | | | 128 | | |
| Other | | | | | 2 | 0 | | | | | | | | | | | | | | | | 2 | | |
| | | | | | | | | | | | | | | | | 2x 99 | | | | | | | | |
| **Sample B** | | 2,97 | 0,061 | 2,1 | 371 | | | | | | | | 0 | | | CRV | 2,993 | 0,045 | 8% | 2,75 | 3,24 | 371 | 368 | 99 |
| (2) Phot. with o-cresolftalexon | | 2,97 | 0,082 | 2,7 | 25 | 0 | | | | | | | | | | | | | | | | 25 | | |
| (3) Photom. with arsenazo III | | 2,97 | 0,063 | 2,1 | 216 | 0 | | | | | | | | | | | | | | | | 216 | | |
| (4) Photomet. with NM-BAPTA | | 2,98 | 0,052 | 1,7 | 128 | 0 | | | | | | | | | | | | | | | | 128 | | |
| Other | | | | | 2 | 0 | | | | | | | | | | | | | | | | 2 | | |
| | | | | | | | | | | | | | | | | 2x 99 | | | | | | | | |
| (36) **Calcium ionised** | [mmol/L] | | | | 65 | | | | | | | | 65 | 62 | 95 | | | | | | | 0 | | |
| **Sample A** | | 1,62 | 0,042 | 2,6 | 65 | | CVP | 1,62 | 0,013 | 10% | 1,45 | 1,79 | 65 | 63 | 97 | | | | | | | 0 | | |
| (2) Direct ISE | | 1,62 | 0,041 | 2,5 | 60 | 0 | | | | | | | 60 | | | | | | | | | | | |
| Other | | | | | 5 | 0 | | | | | | | 5 | | | | | | | | | | | |
| | | | | | | | 1x 0, 4x 1 | | | | | | | | | | | | | | | | | |
| **Sample B** | | 1,71 | 0,05 | 2,9 | 65 | | CVP | 1,71 | 0,015 | 10% | 1,53 | 1,89 | 65 | 62 | 95 | | | | | | | 0 | | |
| (2) Direct ISE | | 1,71 | 0,047 | 2,7 | 60 | 0 | | | | | | | 60 | | | | | | | | | | | |
| Other | | | | | 5 | 0 | | | | | | | 5 | | | | | | | | | | | |
| | | | | | | | 1x 0, 4x 1 | | | | | | | | | | | | | | | | | |
| (6) **Iron** | [µmol/L] | | | | 335 | | | | | | | | 335 | 334 | 100 | | | | | | | 0 | | |
| **Sample A** | | 27,4 | 0,82 | 3 | 335 | | CVP | 27,4 | 0,11 | 15% | 23,2 | 31,6 | 335 | 335 | 100 | | | | | | | 0 | | |
| (2) Method with ferrozine/ferene | | 27,4 | 0,81 | 2,9 | 289 | 0 | | | | | | | 289 | | | | | | | | | | | |
| (4) Method with TPTZ | | 27 | 0,77 | 2,9 | 45 | 0 | | | | | | | 45 | | | | | | | | | | | |
| Other | | | | | 1 | 0 | | | | | | | 1 | | | | | | | | | | | |
| | | | | | | | 1x 99 | | | | | | | | | | | | | | | | | |
| **Sample B** | | 40,4 | 1,5 | 3,7 | 335 | | CVP | 40,4 | 0,2 | 15% | 34,3 | 46,5 | 335 | 334 | 100 | | | | | | | 0 | | |
| (2) Method with ferrozine/ferene | | 40,6 | 1,5 | 3,7 | 289 | 0 | | | | | | | 289 | | | | | | | | | | | |
| (4) Method with TPTZ | | 39,4 | 1,1 | 2,8 | 45 | 0 | | | | | | | 45 | | | | | | | | | | | |
| Other | | | | | 1 | 0 | | | | | | | 1 | | | | | | | | | | | |
| | | | | | | | 1x 99 | | | | | | | | | | | | | | | | | |